| Functional selectivity and classical concepts of quantitative pharmacology JD Urban, WP Clarke, M Von Zastrow, DE Nichols, B Kobilka, H Weinstein, ... Journal of Pharmacology and Experimental Therapeutics 320 (1), 1-13, 2007 | 1306 | 2007 |
| Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology DA Shapiro, S Renock, E Arrington, LA Chiodo, LX Liu, DR Sibley, ... Neuropsychopharmacology 28 (8), 1400-1411, 2003 | 1229 | 2003 |
| Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes CP Lawler, C Prioleau, MM Lewis, C Mak, D Jiang, JA Schetz, ... Neuropsychopharmacology 20 (6), 612-627, 1999 | 584 | 1999 |
| Third generation antipsychotic drugs: partial agonism or receptor functional selectivity? RB Mailman, V Murthy Current pharmaceutical design 16 (5), 488-501, 2010 | 412 | 2010 |
| Serotonergic basis of antipsychotic drug effects in schizophrenia JA Lieberman, RB Mailman, G Duncan, L Sikich, M Chakos, DE Nichols, ... Biological psychiatry 44 (11), 1099-1117, 1998 | 307 | 1998 |
| Aripiprazole has functionally selective actions at dopamine D2 receptor-mediated signaling pathways JD Urban, GA Vargas, M Von Zastrow, RB Mailman Neuropsychopharmacology 32 (1), 67-77, 2007 | 270 | 2007 |
| Smoking duration, intensity, and risk of Parkinson disease H Chen, X Huang, X Guo, RB Mailman, Y Park, F Kamel, DM Umbach, ... Neurology 74 (11), 878-884, 2010 | 268 | 2010 |
| trans-10, 11-dihydroxy-5, 6, 6a, 7, 8, 12b-hexahydrobenzo [a] phenanthridine: a highly potent selective dopamine D1 full agonist WK Brewster, DE Nichols, RM Riggs, DM Mottola, TW Lovenberg, ... Journal of medicinal chemistry 33 (6), 1756-1764, 1990 | 250 | 1990 |
| AF64A, a cholinergic neurotoxin, selectively depletes acetylcholine in hippocampus and cortex, and produces long-term passive avoidance and radial-arm maze deficits in the rat TJ Walsh, HA Tilson, DL DeHaven, RB Mailman, A Fisher, I Hanin Brain research 321 (1), 91-102, 1984 | 250 | 1984 |
| GPCR functional selectivity has therapeutic impact RB Mailman Trends in pharmacological sciences 28 (8), 390-396, 2007 | 240 | 2007 |
| Lower low‐density lipoprotein cholesterol levels are associated with Parkinson's disease X Huang, H Chen, WC Miller, RB Mailman, JL Woodard, PC Chen, ... Movement disorders: official journal of the Movement Disorder Society 22 (3 …, 2007 | 237 | 2007 |
| Simultaneous quantification of dopamine, 5-hydroxytryptaine and four metabolically related compounds by means of reversed-phase high-performance liquid chromatography with … CD Kilts, GR Breese, RB Mailman Journal of Chromatography B: Biomedical Sciences and Applications 225 (2 …, 1981 | 220 | 1981 |
| Interactions of neurotensin with brain dopamine systems: biochemical and behavioral studies. CB Nemeroff, D Luttinger, DE Hernandez, RB Mailman, GA Mason, ... Journal of Pharmacology and Experimental Therapeutics 225 (2), 337-345, 1983 | 212 | 1983 |
| A selective D-1 dopamine antagonist with potent D-2 behavior actions. RB Mailman Eur J Pharmacol 101, 159-160, 1984 | 195 | 1984 |
| Dihydrexidine, a full dopamine D, agonist, reduces MPTP-induced parkinsonism in monkeys JR Taylor, MS Lawrence, DE Redmond Jr, JD Elsworth, RH Roth, ... European journal of pharmacology 199, 389-391, 1991 | 184 | 1991 |
| Low LDL cholesterol and increased risk of Parkinson's disease: prospective results from Honolulu‐Asia Aging Study X Huang, RD Abbott, H Petrovitch, RB Mailman, GW Ross Movement disorders: official journal of the Movement Disorder Society 23 (7 …, 2008 | 177 | 2008 |
| Long-term effects of early social isolation in Macaca mulatta: changes in dopamine receptor function following apomorphine challenge MH Lewis, JP Gluck, AJ Beauchamp, MF Keresztury, RB Mailman Brain Research 513 (1), 67-73, 1990 | 176 | 1990 |
| Quantitative susceptibility mapping of the midbrain in Parkinson's disease G Du, T Liu, MM Lewis, L Kong, Y Wang, J Connor, RB Mailman, X Huang Movement Disorders 31 (3), 317-324, 2016 | 173 | 2016 |
| Projection of the prevalence of Parkinson's disease in the coming decades: Revisited A Rossi, K Berger, H Chen, D Leslie, RB Mailman, X Huang Movement Disorders 33 (1), 156-159, 2018 | 169 | 2018 |
| Novel dopamine therapeutics for cognitive deficits in schizophrenia AFT Arnsten, RR Girgis, DL Gray, RB Mailman Biological psychiatry 81 (1), 67-77, 2017 | 168 | 2017 |
Xuemei HuangDistinguished Professor, Pennsylvania State University College of MedicineBestätigte E-Mail-Adresse bei psu.edu
